Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. - Wikidata - awgldk - TriplyDB

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

http://www.wikidata.org/entity/Q43648194

about

Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review Cost-effectiveness of extended-release methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder sub-optimally treated with immediate release methylphenidate Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan Extended-release medications for children and adolescents with attention-deficit hyperactivity disorder The meaning of attention-deficit/hyperactivity disorder medication and parents' initiation and continuity of treatment for their child Concordance between parent and physician medication histories for children and adolescents with attention-deficit/hyperactivity disorder.Attention-deficit/hyperactivity disorder and risk of substance use disorder: developmental considerations, potential pathways, and opportunities for research.Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands.Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades.Treatment planning for children with attention-deficit/hyperactivity disorder: treatment utilization and family preferences.Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.Promoting productive interactions between parents and physicians in the treatment of children with attention-deficit/hyperactivity disorder.A waitlist-controlled trial of behavioral parent training for fathers of children with ADHD Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.The NICE ADHD health technology assessment: a review and critique Relationship Between Attention-Deficit/Hyperactivity Disorder Care and Medication Continuity.Emerging drugs for attention-deficit/hyperactivity disorder.Injury among stimulant-treated youth with ADHD.Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey.The impact of long-acting medications on attention-deficit/hyperactivity disorder treatment disparities.A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.Global issues related to the impact of untreated attention-deficit/hyperactivity disorder from childhood to young adulthood.Improving psychostimulant adherence in children with ADHD.Parental etiological explanations and longitudinal medication use for youths with attention deficit hyperactivity disorder.Review of medication adherence in children and adults with ADHD.Enhancing ADHD medication adherence: challenges and opportunities Attention-deficit/hyperactivity disorder: an update on medication adherence and persistence in children, adolescents and adults.Barriers to evidence-based treatment for children with attention-deficit/hyperactivity disorder.Systematic Review of Patients' and Parents' Preferences for ADHD Treatment Options and Processes of Care.Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study.Impact of Attention-Deficit Hyperactivity Disorder on School Performance: What are the Effects of Medication?Racial and Ethnic Differences in ADHD Treatment Quality Among Medicaid-Enrolled Youth.Efficacy of a family-focused intervention for young drivers with attention-deficit hyperactivity disorder.To adhere or not, and what we can do to help.Comorbidity and Factors Affecting Treatment Non-Persistence in ADHD.Adherence with electronic monitoring and symptoms in children with attention deficit hyperactivity disorder.Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed?

P2860

Q26822392-B610A387-BE2F-4A6B-9A81-5F8F081CFCE2 Q26859455-F0CA44E7-377F-4510-ADB5-63BBFBCBA740 Q28547634-A629C950-0475-490B-AFD6-26A0052EB754 Q28553475-7D14A25B-FD43-426C-80F6-B4028C0D1D08 Q33588902-1287BFE9-A921-4CDC-9171-B8E0AC6E0F2B Q33694953-B0DA10DA-FF60-4CC1-AA4D-E20BA1F23924 Q33782808-EC09AD8A-E82C-440F-98F9-1C05C4A1B2DF Q33900589-E3CD9646-2E8F-41B4-A1DF-3204D16526D5 Q34286130-F145915A-7FE2-4657-9B2F-050E96ADF473 Q34400595-67FBCE5E-C966-4451-AAD7-90689E8D493A Q34440332-9FDB8915-26B1-4D3C-BE27-6070D3B0AA2A Q34554876-416D8DC2-F80A-4754-B3A9-8B6A188FC935 Q34808555-374B051F-0A4A-4416-AF2F-0BA9419D7C4A Q35135055-8DEE2322-D5B4-49E1-9C33-64CF4B6166F3 Q36052887-EFAAB2CC-E1CC-4015-9959-258E01B1FF48 Q36409734-95059D8E-C01D-4C8A-B31C-A53FC570C74F Q36469468-5D4C3327-0B2F-4270-980B-D11F7D17684E Q36491460-00E8D95F-9FBE-4EE6-BF2A-5EBC3E3262F3 Q36731199-6E2596A6-1B69-437A-B632-09CF76C7FFFA Q36944017-A1AA1B0F-8443-4D80-94B5-5E7496106B67 Q36969976-EB7033AD-EE40-4CED-95C7-C5FA23F3B11B Q36986830-23E4E5FF-D595-4D47-8CA6-8DA7DA8D09B1 Q37111459-7B0A671C-A97D-49AA-97AB-B81FBDF49A2D Q37190656-7DF6CE42-CBCC-4605-BC05-B56EFF0F084A Q37282163-832DE5FF-6BFB-41BB-8D18-3D847C31EC4B Q37301222-B5FEE908-58FC-466F-ABCF-45D0C888F11A Q37395645-783C0973-99C0-4805-8D6D-512E1D7C1987 Q37682563-42A2DC4F-07FC-4323-89D4-23AC8E635A2F Q38109853-5C155750-07B7-4134-B294-04AEBEDD6280 Q38161921-594DBA7D-927A-438F-9A3D-60FBD821DF79 Q38233243-1A5D0C4D-97F2-4444-AE1A-B76119D43151 Q38341402-1B26F107-5976-4D5F-A2EB-46FF55E7E959 Q38418781-9448D7B8-BCA0-4D8E-8A12-FFFFD6B7225F Q38563913-A6AC0304-CD12-4C48-987D-BD677461BBD0 Q38754186-8606F47B-98EC-4FCF-89AD-24918A62FB82 Q39400638-2976D5E8-57E6-409C-995A-6ACB21D60276 Q39559078-96A880EF-80BA-4E70-8291-79DA478F4C19 Q40905411-821365BD-D09F-4081-BBC6-2D690DB6977B Q41778673-EBFCDD0E-D7C3-47A1-9B87-99A4094BAE10 Q42113942-4AB3AF14-0B2C-4751-8D57-A5A62A69EABF

P2860

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

http://www.wikidata.org/entity/Q43648194

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

@en

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

@nl

type

label

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

@en

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

@nl

prefLabel

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

@en

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

@nl

P1433

Q43648194-DB366160-E0D9-485D-85D0-5445DBF0113B

P1476

Q43648194-895A8AC4-CFB7-4B6D-B0CB-C77F85894FD3

P2093

Q43648194-5DD1C579-5E75-4291-AA10-9F82AC25D754

Q43648194-B312185D-731C-41E5-8C58-E80F9BD9216B

Q43648194-F3E9F68E-959D-4E6B-B487-26461592F047

Q43648194-FB444621-9171-4401-9237-F62BDAE0F1E5

P304

Q43648194-AE66665C-85A8-49A2-A4D2-B0657E176548

P31

Q43648194-5A389C9D-6B1E-4C13-8C4B-259D1F6C564C

P356

Q43648194-E6A6DA69-1444-436B-A678-D912EA7A49FB

P407

Q43648194-B57C5565-154C-4FB4-A3CE-2917A5B2ACD2

P433

Q43648194-B6EB3E0F-D7A9-48D1-9175-97B3693880DA

P478

Q43648194-33C1DF07-FF45-4847-9DD9-D0812DB72045

P577

Q43648194-0F6A28BC-734E-4E29-B937-EA9FD584FFB5

P698

Q43648194-D493807E-DDDC-42BC-845F-860538B5A45F

P921

Q43648194-C41CAAB3-292A-4315-B12A-441853FA3764

P356

ARCHPEDI.159.6.572

P1433

JAMA Pediatrics

P1476

Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.

@en

P2093

George J Wan

http://www.w3.org/2001/XMLSchema#string

Jason E Kemner

http://www.w3.org/2001/XMLSchema#string

Mark Olfson

http://www.w3.org/2001/XMLSchema#string

Steven C Marcus

http://www.w3.org/2001/XMLSchema#string

P304

572-578

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHPEDI.159.6.572

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

159

http://www.w3.org/2001/XMLSchema#string

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15939858

http://www.w3.org/2001/XMLSchema#string

P921